Latham & Watkins advises Mainstay Medical in the context of the delisting of its shares from Euronext Paris

This unprecedented transaction consisted in the implementation of a "scheme of arrangement" by an Irish entity to delist its shares from Euronext Paris.

11/06/2020

Mainstay Medical International plc, an Irish company whose securities are listed on the regulated market of Euronext Paris and on the Euronext Growth market in Dublin, announced on 5 June the completion of an Irish scheme of arrangement procedure under which Mainstay Medical's shareholders received one share of a new unlisted Irish holding company. The completion of the transaction is followed by the delisting of the company's shares from Euronext Paris and Euronext Growth in Dublin with effect on June 8, 2020.

Mainstay is a European medical device company focused on bringing to market an innovative implantable neurostimulation system, ReActiv8, for people with disabling Chronic Low Back Pain. 

Latham & Watkins advised Mainstay Medical International plc on this transaction with a Paris team led by partner Pierre-Louis Cléro and counsel Semih Bayar Eren, assisted by Philippe Tesson on corporate aspects. Partner Xavier Renard assisted by Clémence Morel, advised on the tax aspects.

 
 

Avertissement : Nous vous remercions de l’intérêt que vous portez à Latham & Watkins. Si vous souhaitez nous confier un dossier mais que vous n'êtes pas encore client du cabinet, merci de ne nous transmettre aucune information confidentielle. Nous ne pouvons pas accepter un dossier avant de nous être assurés que nous sommes en mesure de vous assister et d’avoir trouvé un accord avec vous sur les termes et conditions de notre intervention. Dans la mesure où nous n’aurons pas de relation avocat-client avec vous auparavant, nous n’aurons aucune obligation de confidentialité à l’égard des informations que vous nous auriez transmises. Merci de votre compréhension.